{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-040725","form_type":"8-K","ticker":"ASBP","cik":"0001847345","company_name":"Aspire Biopharma Holdings, Inc.","filed_at":"2024-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.017075+00:00","generated_at":"2026-05-30T16:52:47.098384+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"PowerUp extends Aspire merger disclosure schedule delivery to Oct 11, 2024","bullets":["Second Amendment Agreement moves Disclosure Schedule Delivery Date to October 11, 2024.","Allows additional time for due diligence and compilation of disclosure schedules.","No changes to merger consideration, equity incentive pool, or other key terms.","Amendment is in connection with the previously announced business combination with Aspire Biopharma."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-040725","json":"https://secwatch.observer/filing/0001493152-24-040725.json","markdown":"https://secwatch.observer/filing/0001493152-24-040725.md","text":"https://secwatch.observer/filing/0001493152-24-040725.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847345/000149315224040725/0001493152-24-040725-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847345/000149315224040725/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T16:52:47.098384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}